(opens original source in a new tab)STAT NewsSTAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
(opens original source in a new tab)STAT NewsSTAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and moreRoche's Genentech will invest $750 million to double the size of its existing production facility in Oregon (opens original source in a new tab)Ed Silverman·21 August 2026
(opens original source in a new tab)STAT NewsSTAT+: Are cancer patients getting too much drug?Moderna's stunning surge and drop, AI in scientific writing, and more biotech news from The Readout (opens original source in a new tab)Meghana Keshavan·21 August 2026
(opens original source in a new tab)STAT NewsScientists deploy Merck’s Ebola vaccine in DRCProstate cancer therapy, Meta glasses in hospital settings, and more health news from Morning Rounds (opens original source in a new tab)O. Rose Broderick·21 August 2026
(opens original source in a new tab)STAT NewsFocal therapy for localized prostate cancer has divided physicians. Will new data change minds?Urologic oncologists who treat prostate cancer are split over the benefits of focal therapy compared to traditional surgery or radiation. (opens original source in a new tab)Annalisa Merelli·21 August 2026
(opens original source in a new tab)STAT NewsOpinion: Lil Nas X’s bipolar diagnosis and the paradox of treatmentWe continue to romanticize the symptoms of mental health problems, especially when we talk about achievement. (opens original source in a new tab)Rachel Docekal·21 August 2026
(opens original source in a new tab)STAT NewsOpinion: A cure for HIV would be a triumph. But it shouldn’t harm survivorsLong-term survivors deserve to see a cure, not fear the losses it might bring. (opens original source in a new tab)Ali Ahmed, Jeff Taylor,and Jeff Berry·21 August 2026
(opens original source in a new tab)STAT NewsSTAT+: How a Trump loyalist got the FDA nominationWhat you need to know about Heidi Overton, and Erica Schwartz's first speech to CDC staff. (opens original source in a new tab)John Wilkerson·20 August 2026
(opens original source in a new tab)STAT NewsSTAT+: FDA approves Ultragenyx gene therapyRegeneron wins ultra-rare disease drug approval, a validating win for mRNA research, and more biotech news from The Readout (opens original source in a new tab)Meghana Keshavan·20 August 2026
(opens original source in a new tab)STAT NewsContrasting legal decisions on gender-affirming careHeidi Overton's rise under Trump, inside a 5-year-old brain organoid, and other health news from Morning Rounds (opens original source in a new tab)Theresa Gaffney·20 August 2026
(opens original source in a new tab)STAT NewsSTAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and moreA Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effort (opens original source in a new tab)Ed Silverman·20 August 2026
(opens original source in a new tab)STAT NewsSTAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejectionCapricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy. (opens original source in a new tab)Adam Feuerstein·20 August 2026
